

Supplementary Table S20. Win ratio analysis to evaluate the hierarchical composite endpoint in non-ACLF.

Outcome	High risk % wins	Low risk % wins	Win ratio (95% CI)	Win odds (95% CI)	Net benefit (95% CI)	P-value for Win ratio
Composite endpoint of 90-day death, organ failure ≥ 1 , sepsis, new onset AD within 1 month and SIRS	36.2	5.1	7.13 (3.66-13.89)	1.90 (1.45-2.51)	0.31 (0.17-0.45)	<0.001
Composite endpoint of 28-day death, 90-day death, organ failure ≥ 1 , sepsis and SIRS	31.8	3.3	9.72 (4.66-20.24)	1.80 (1.39-2.32)	0.28 (0.16-0.41)	<0.001
Composite endpoint of 90-day death, organ failure ≥ 1 , sepsis, SIRS and new onset AD within 1 month	36.3	4.9	7.26 (3.72-14.19)	1.91 (1.45-2.52)	0.31 (0.18-0.45)	<0.001
Composite endpoint of 90-day death, sepsis, new onset AD within 1 month and SIRS	33.8	4.4	7.68 (3.83-15.40)	1.83 (1.40-2.39)	0.29 (0.16-0.43)	<0.001
Composite endpoint of 90-day death, organ failure ≥ 1 , sepsis and SIRS	31.7	3.2	9.92 (4.75-20.73)	1.80 (1.39-2.33)	0.29 (0.07-0.45)	<0.001
Composite endpoint of 90-day death, sepsis, organ failure ≥ 1 and SIRS	31.7	3.1	10.07 (4.82-21.05)	1.80 (1.39-2.33)	0.29 (0.16-0.42)	<0.001

Note: ACLF, acute-on-chronic liver failure; AD, acute decompensation; SIRS, systemic inflammatory response syndrome.